Sheff Station
Contributor since: 2010
Latest Articles
Is Celldex Poised for a Comeback?
Acquisition Talks of Amarin Continue to Progress
Maximizing Opportunity and Minimizing Risk With Trading FDA Decisions
Tracking Short Positions of 3 Biotechs With PDUFA Dates in January
Celsion Positioned for Breakthrough Year in 2011
Will the Nuedexta Launch Transform Avanir Into a Mature Biotech?
DepoMed vs. InterMune: Vastly Different Market Caps, Both Seeking FDA Approval
3 Catalysts That Could Push DepoMed Share Price Higher
Capstone Therapeutics Looking to Capitalize on the Growing Dermal Market
Cytokinetics Poised for Uptick in 2011
December Will Be Exciting for Up and Coming Corcept Pharmaceuticals
Cumberland Pharma Is Flying Under the Radar
Soon-To-Be-Released Data Poised to Propel AEterna Zentaris Value
Amarin: Pending Catalysts, Potential Breakthrough
Cadence: Patient Investors Should Watch Short Sellers Before FDA Decision on Thursday
November Could Be a Big Month for Biotech Aastrom
Approval of Questcor's Athcar Drawing Near
Risks vs. Benefits in Holding Alexza Through Approval of AZ-004
Biosante: Key Catalysts Should Renew Investor Interest
Avanir Trading Volatility and Increased Short Interest in September Provides Promising Opportunity
Alexza's Staccato: Setting Up as a New Platform for 'Inhalation Technology'
Questcor Pharma: Acthar Approval Seems Likely
Avanir Expected to Shine at the American Neurological Association Meeting
Alexza Pharma Clears Hurdles Towards Approval for Agitation Drug
Alexza Financing Will Help Near-Term Milestones and Product Launch
Avanir’s STAR Trial: Offering Clarity to the FDA
The Value of an SPA for Avanir Pharmaceuticals